OptimizeRx Corporation (OPRX) Earnings Call Transcript
November 6, 2025
Earnings Call Speaker Segments
Thanks, operator, and good afternoon, everyone, on our Q3 2025 earnings call. It was a solid third quarter, with results surpassing consensus estimates as well as what we had expected internally. Q3 revenues rose 22% compared with a year earlier, reaching $26.1 million, while adjusted EBITDA came to $5.1 million — more than $2 million better than the prior-year period. Contracted revenue continues to run significantly ahead of last year's pace, which highlights how well our emphasis on operational excellence is working, along with our commitment to delighting customers and deepening ties with trusted partners. Before moving ahead, I'd like to pause and thank the OptimizeRx team. We truly appreciate how dedicated and hardworking they are as we steer through a digital pharma marketing landscape that grows more complex and evolves more quickly all the time. A major transformation is underway across the industry, and the company's offerings are set up to fundamentally reshape the way pharmaceutical companies, patients and prescribers connect. Our mission-driven culture powers this momentum and lets us draw in, keep and reinforce the relationships that establish us as a trusted, enduring technology partner. That said, I'm pleased to share that we're raising guidance for the year, expecting revenue of between $105 million and $109 million, with adjusted EBITDA of between $16 million and $19 million. Also, though it's still quite early, RFP trends for 2026 look favorable. Because of that, we're introducing initial fiscal year 2026 guidance, with revenue anticipated to land between $118 million and $124 million and adjusted EBITDA anticipated to land between $19 million and $22 million. Additionally, after our third quarter ended, we repaid an extra $2 million toward our term loan principal beyond the scheduled debt payments. Right now, based on the cash flow we're seeing, we plan to keep reducing our debt at a faster pace and don't expect to need equity capital markets access for the foreseeable future. As our strong results show, we are clearly hitting our stride. Disciplined cost management and targeted cross-selling strategies rooted in helping customers optimize budget allocation and maximize script lift are producing sustained momentum as we head into Q4 2025 and past it. Our strong third quarter performance makes it obvious that becoming a sustained Rule of 40 company is within reach. Maybe most notably, average revenue from our 5 largest customers across the last 12 months keeps climbing and now exceeds $11 million; we believe OptimizeRx holds a unique position to deliver meaningful long-term growth and sustainable shareholder value. With one of the nation's largest point-of-care networks, we give pharmaceutical manufacturers the ability to reach health care providers directly at the moments that matter most. Building on that foundation, we've created a purpose-built omnichannel technology platform that brings together advanced patient finding tools such as DAAP and micro neighborhood targeting. What these tools are doing is changing the way drugmakers, doctors, and patients interact, exchange information, and take action, which helps boost patient results while overhauling how the whole health care system engages. Having a footprint in both the point-of-care and direct-to-consumer spaces gives us a competitive edge that is built to last and hard to copy. No other company besides OptimizeRx combines the size, tech, and data connections needed to bring providers and patients together so smoothly, which lets us offer the sector's most complete commercialization platform; because of that, we can serve clients throughout the entire product life cycle, strengthen ties with them, and secure a bigger portion of value over the long haul. As we've mentioned on earlier calls, one main priority going forward is to better highlight what we can reach, how we can scale, and the fact that we serve as a dependable strategic ally, assisting drug manufacturers in tackling some of their toughest commercialization hurdles; among these are boosting brand awareness, cutting down on prescription abandonment, enhancing interoperability, and backing the rising move toward complicated specialty drugs. The strongest proof of how well we help clients overcome these hurdles, I think, is our proven capacity to expand upon relationships and grow our engagements with our biggest clients. I have no doubt that ongoing progress in these areas, paired with our knack for producing solid ROI and generating impact and script lift for clients, will turn into significant long-term shareholder value. We feel our momentum puts us in position to grab more market share and grow our involvement in the pharma industry's digital ecosystem, which is worth billions. Our clients stay closely tied to our combined HCP and DTC offerings, and we aim to keep them involved throughout the entire patient care journey; with that said, I want to hand the call over to our CFSO, Ed Stelmakh, who will take us through the financial results. Ed?
Appreciate that, Steve, and welcome this afternoon, everybody. We put out a press release covering the financial results for our third quarter that closed on September 30, 2025. You can view a copy and download it from the Investor Relations area of our site, and you can find more details in our upcoming 10-Q. Revenue for the third quarter reached $26.1 million, which is up 22% compared with $21.3 million in the equivalent period of 2024. Gross margin rose from 63.1% in the quarter that ended September 30, 2024, to 67.2% in the quarter that ended September 30, 2025. That year-over-year gross margin improvement reflects a beneficial product mix, economies of scale, and a beneficial channel partner mix. Operating expenses for the quarter that ended September 30, 2025, declined by $6.5 million versus the prior year to $15.5 million, since last year's third quarter included a $7.5 million impairment charge. At the same time, our cash OpEx climbed to $12.4 million from $10.8 million, mainly because of larger bonus and commission payouts, which are directly linked to the company's robust year-to-date performance. Consequently, we recorded GAAP net income of $0.8 million, or $0.04 per basic and fully diluted share, for the 3 months that ended September 30, 2025, versus a GAAP net loss of $9.1 million, or $0.50 per basic and fully diluted share, for the identical 3-month period in 2024. On a non-GAAP basis, net income for the third quarter of 2025 was $3.9 million, or $0.20 per fully diluted share outstanding, compared with non-GAAP net income of $2.3 million, or $0.12 per fully diluted share outstanding, in the same period a year ago. Adjusted EBITDA reached $5.1 million for the third quarter of 2025, versus $2.7 million in the third quarter of 2024. Operating cash flow totaled $11.6 million for the first 9 months of 2025, and we finished the quarter with a cash balance of $19.5 million, compared with $13.4 million on December 31, 2024. The outstanding principal on our term loan debt financing at the close of the third quarter was $28.8 million. And after the quarter closed, we repaid an extra $2 million of principal, bringing total principal paydown for the year to $7.5 million. Right now, we plan to pay down the term loan principal more quickly than we initially anticipated, as we aim to keep reducing our cost of capital. Having said that, we still believe our strong balance sheet will support us in executing against our operational goals. Now let's move to our KPIs for the third quarter of 2025. Average revenue per top 20 pharmaceutical manufacturer is now $3.1 million, compared with $2.9 million for the third quarter of 2024. Net revenue retention rate stayed solid at 120% Meanwhile, revenue per FTE reached $820,000, surpassing the $732,000 we reported in the third quarter of 2024. Seeing our KPIs get better is heartening, and we'll keep carrying out our plan of generating profitable growth while being a top player in our market. With that said, I'll now hand things back to Steve. Steve?
Thank you, Ed. Operator, now let's move to Q&A.
My apologies, everyone — is my voice coming through at this point? Good. Can everyone hear me clearly now?
Ryan, we've got you.
All right, my apologies for that. Congratulations on the impressive results. I'd like to begin with the 2026 outlook. It's great to see that provided so early in the year — very few companies do that. And I'm wondering if you could give a bit more detail on the reasoning behind sharing it now. My assumption is that it relates to improved visibility stemming from the contracts. Then, for my second question, you brought up the robust RFP activity as a factor in that. Are you simply observing additional new clients? Is there a greater move toward digital, toward omnichannel, toward HCP because of certain D2C difficulties? Any insight into what's fueling that? Congratulations once more.
Thank you, Ryan. Great to hear from you. Let me take the first one. We've been consistently telling the Street, as well as our clients and investors, that we intend to provide greater visibility regarding our ability to see into the future, since we've been shifting increasingly toward a predictive model — something we've referenced previously, called subscripted momentum. So we'll keep advancing that for the rest of the year. Because of that, we're now gaining improved visibility into future years, 2026 included. Regarding the RFP situation, Ryan, this RFP season has been extremely robust for the business. We are seeing additional participants entering the digital arena and making investments on the client side; and at this stage we're witnessing equal portions of HCP and DTC interest within the RFP cycle. I'd note that the DTC segments we serve at OptimizeRx are CTV, ATV — the areas you're familiar with. And should there be a linear television ban, a reduction, or anything along those lines, our perspective and thesis is that our solutions would keep benefiting disproportionately from such developments. So as of now, I'd say both DTC and HCP appear quite healthy. Thanks for the question.
If you consider what the guidance implies for Q4 revenue, at the high end it would really be a bit lower than the same period a year ago. Could you address whether there were any one-time items in that year-ago quarter, or anything else, since your net retention would suggest that doing so is kind of hard?
Yeah. Appreciate that question, Rich. Nice to hear from you. What we're really doing is looking at a guide for the whole year right now and attempting to provide a solid range for what we think we'll land at. As everyone listening knows, we stopped giving pipeline figures and shifted mainly to contracted revenue and the actual visibility we have. So the updated guidance we've put out genuinely reflects that visibility. It leaves out bluebirds that could occur, buy-ups that could occur, which aren't factored in at present and where we lack visibility; in prior years, we'd have considered those more through pipeline and probabilities. But I believe what you see in the guidance today mirrors the genuine visibility we're confident we can hit. Once more, we'll keep being extremely transparent and extremely conservative — not sandbagging — while aiming to exceed the figures we release each time. So I hope you value that transparency and conservatism.
Allow me to tack on a small point. Like Steve mentioned, my view is that we ought to examine this across an entire year instead of evaluating each quarter separately. Q1, 2 and 3, as you're aware, came in exceptionally strong. Consequently, the phasing this year is a bit more even than has been the case previously; so once more, I'd simply urge you to consider how the whole year compares against the prior year.
And a piece of that comes from the improvements we've made to how we bring in money, correct, Rich — another piece is that we've managed to move off those step-downs in revenue that happen at intervals, reaching instead a revenue model that's smoother. That's the thing Ed means when he says that.
Understood. Looking at it as though it were a complete year is simply a bit tough, since merely 90 days remain. So I imagine my question will receive a comparable response; still, when examining the adjusted EBITDA guidance, you would see a revenue quarter that rises, perhaps by 10% or more on a sequential basis, yet adjusted EBITDA might decline slightly or, within a narrow margin, conceivably increase. Once more, are there any sort of one-time costs, year-end items that adjust upward and produce a greater headwind, because it would not — it would also remain lower versus the prior year.
Certainly. Ed, would you like to address that one?
Sure, I'll handle that question. Yeah, so what we're doing is using a cautious gross margin figure. Nothing on the opex side is really going to jump out. So it's mostly about being somewhat more cautious regarding your expectations for how the channel and product mix will play out; our aim, we do believe, was to reach or exceed the upper end of that range.
Perhaps you could elaborate slightly on that topic we were just discussing. Steve, could you spend a moment reminding us at a basic level what might be happening within the business that could be evening out the quarters or perhaps providing improved visibility? I have a follow-up after that, but I'm just wondering, again, at a fundamental level, about some of the adjustments you folks have implemented that might be generating somewhat enhanced visibility and, once more, giving you the assurance, for instance, to provide guidance for 2026 right now.
Certainly. Sure, happy to take that one, and Andy and Ed might want to jump in as well. But when you look at our business data the way we've framed it over time, there are our audience businesses, which are mostly GAAP, and then there's micro neighborhood audience, the targeting capability for DTC. Both of those are data-driven technologies, and both lend themselves to becoming more subscription-like in nature. Then you've got our execution functions, at point of care and the other omnichannel pieces for HCP, plus the same for DTC. Those are clearly going to be mostly transactional, simply because that's how that part of not only our business, but the ecosystem, works. What we've seen, as we've talked about in prior months, is DAAP growing beyond expectations, along with micro neighborhood audiences coming back strong. Those elements don't just help even out our revenue thanks to how those revenue models work—they also give us a forward-looking, recurring window into 2026, and those agreements kick in sooner than our typical transaction level contracting would. That's really the main piece of it. Andy, Ed, jump in if either of you wants to add anything.
Yeah. What I meant was — please continue, Ed.
Actually, what I wanted to mention is that, as all of you are aware, the bulk of what we do is generated through renewals. So when you factor that in, and then layer on certain wins that propelled us through this year, plus the greater clarity we now have regarding next year when it comes to contracts already signed as of today, we believe we're able to state that, okay, when we look ahead to next year, we can begin providing at minimum a broad set of targets we intend to pursue. And as matters move along, we'll keep narrowing that spread. Yes, please go ahead, Andy, feel free to chime in.
Nope, that's right. The two of you hit it on the head.
Appreciate all of that context. If my memory serves me, during the prior quarter we discussed those managed services-style agreements that get signed. What portion of that showed up in Q3? And are you applying the same presumption as you did a quarter ago, meaning you're not factoring in any of that landing in Q4 when it comes to the guidance you gave, plus the '26 outlook? Should we be thinking about it that way?
Yeah. Andy, would you like to handle that question?
Yes. In Q3, that managed services business returned to something closer to a typical level. When it comes to the forecast period for managed services, the only items we're putting in are those already booked that are beginning to convert into revenue at this moment. Anything sitting in the pipeline that lacks visibility for us is essentially left out. So once more, our guidance approach is quite cautious, built on bookings we have strong confidence in.
Right. When we consider your '26 guidance, could you help us frame the retention level that serves as the baseline, so to speak, for hitting that range?
Yes. Each year, new logos have historically accounted for 5% to 15% of our business; the rest, then, is what you'd call net revenue retention on a normalized basis.
Okay. And does the same assumption sit beneath your '26 guidance?
It does.
Yeah. We don't actually provide guidance tied to net revenue retention, correct, though that's roughly the way it works out as each year moves along.
And David, regarding that, here's one more brief item for you. Just — you and I discussed this when we last got together. We're noticing solid expansion in the mid-tier portion of our business, which is to say the mid-tier portion of customers arriving who might not belong among those top 20, 25, 30 manufacturers showing up with outsized spend, largely since we can deliver capabilities that supplement — not merely supplement, honestly, take over much of what they cannot manage to handle in-house. . While the large manufacturers could have what you might call Cadillac support, mid-tier companies don't. Yet leveraging the technology we possess lets them compete on equal footing; and that's the reason we're witnessing such momentum there. Within our commercial organization, which Theresa heads, has done a fantastic job of pushing that; so I simply wanted to highlight that as an important point.
I'd like to dig into what's happening with RFPs. You mentioned things have gotten better. What I'm wondering is whether your success percentage has stayed level while the total count of RFPs went up? Or are you winning more often even though the RFP pipeline isn't growing? What's your read on that?
Sure, I'll take that first, and then Andy can add his thoughts as well. It's really all of those things, Eric — we're seeing a greater volume of RFPs arrive, and they're aimed much more squarely at the areas we'd like them to target, which I consider a positive. The marketplace is observing how we're evolving the business model over time; so the RFPs clearly mirror what we're delivering to the market and to our clients; and I'd say our success percentage is consequently improving. Once again, I want to recognize our commercial team. They're doing a fantastic job staying ahead of all of this and connecting with clients; and when your client engagement is closer, you're often able to influence how the RFPs get shaped so they're drafted at a suitable level for something you can actually bid on, rather than being just some arbitrary spray and pray request for information, correct? And whenever we receive those, our success rate ends up lower since there was no relationship established beforehand. So credit goes to Jen Dwyer, Theresa Greco and the whole commercial team for their excellent work on that front.
Understood. Then you brought up how the business has become smoother. Perhaps a quick walkthrough would help me on the transactional side, since you mentioned those got going at a later point in the year, unlike DAAP plus the micro neighborhood, which tend to be more evenly spread and launch each of those campaign varieties.
Absolutely. Glad to get into that. When you consider what DAAP does and what MNT, or MNA, handles, it's mainly about building audiences, and data is what powers every one of those campaigns, correct? The technology is what generates — locating those patients no matter where they happen to be. And since that leans more toward a software-style model, it fits a standard planning calendar in which renewals occur sooner. That's how pharma handles that portion of its budget, and after that come the transactional pieces, which usually means message distribution, be it at an HCP level or something running through a DSP such as a trade desk or through another route, and that is generally budgeted and accounted for quarter by quarter, tied to performance and steered that way. So putting DAAP on the table and bringing it to greater maturity, which we've worked extremely hard at, as you're aware, across the last several years from when we launched it, and now folding in what we gained via the Medicx acquisition with MNT, that has genuinely begun reshaping the business's profile, and that is what shows up in how this year has performed too. You can see it right at the forefront, and it will carry into 2026 as well. That has handed us terrific visibility. I believe everybody has a better feeling about our efforts there. For next year, our visibility is up substantially compared to a year ago.
When it comes to 2025 and 2026, how should we properly consider the share of revenue split across those 2 buckets?
That's not something we disclose. At the product level, we don't disclose it either.
Nice work on yet another impressive quarter. To begin, might you share a bit more detail regarding the Lamar Advertising tie-up and how big this chance could be? Also, I'm curious whether it will be introduced gradually in certain markets, or whether it's launching immediately across all of their national inventory?
Sure. Glad to discuss that. Good to hear from you. The core concept behind the Lamar relationship is that they want to reinvent how they operate, correct? Right now, their model revolves around billboards. One area where OptimizeRx truly excels — something you know very well — is locating patients and being able to target messaging more precisely throughout our omnichannel ecosystem; so imagine applying that strength to support a display situated in a far-off spot that could shift from being just a random billboard to perhaps a big digital screen, correct? That's precisely what Lamar is pursuing. The scale of this chance is enormous. I won't try to estimate the TAM, since it isn't something I should guess at — it genuinely belongs to them. That said, the rollout of this partnership should happen fairly quickly, I'd say; and quoting forecasts for what we expect it to deliver is still premature; right now it's truly in the pilot phase, though we feel quite positive about the early testing we've completed. Once we have additional results, we'll share more details, but the early signs appear quite promising.
Understood. So the guidance you just gave for 2026 — does it include anything at all from that partnership?
Nope, nothing, zero. It's simply too soon for us to begin putting that into a forecast; at this point, we won't be doing so.
Also, could you discuss how gross margin improved during Q3? What was the main factor behind that? And what's the right way to think about margins for Q4 as well as looking ahead to 2026?
Of course. Ed, would you like to handle that question?
Yeah, absolutely. Yeah, so I mean, this usually comes down to what products or solutions we're selling and which channel partners we're working with. Like we've mentioned previously, as the business grows, we get a lot more leverage to secure better terms with our channel partners, and that shows up in the figures, plus the expansion in DAAP and the DTC platform. So those two factors combined got us to where we are now for the year in Q4. Looking ahead, I'd say we're sort of leveling out in that upper 50s to low 60s range based on guidance. But you can definitely see there's potential for that number to go higher as the year goes on.
One quick point to add there, Anderson. In Q2, managed services revenue was much higher for us, while in Q3 we had far less of it, and managed services revenue is the product with our lowest margin.
I'd like to ask about the 2026 guide and profitability. If I do the math at the midpoint, I get roughly 60 basis points of EBITDA margin expansion. Could you discuss how much of the gross margin expansion might come from channel mix versus operating leverage? And are there any areas of potential variability that might cause margin expansion to be greater or smaller than what we see at the midpoint?
Jeff, I'm glad to address that at a high level, and we won't dive too far into 2026, but I'm glad to address it at a high level. What Andy just said really lays out clearly the dynamics of the business that truly drive it, correct? So as our audiences keep growing over time through the DAAP and MNT products, margin expansion will remain front and center, and on the other side we'll also manage the channel partner mix, seeking optimal margin, and that gives us the dynamic of being able to keep improving over time. Execution will be whatever it is, as you know, with this business, and that's fairly predictable in terms of the highs and lows; but those are the dynamics that are sort of shaping how we think about 2026 gross margin expansion opportunities and where we've ended up. Hopefully, that helps.
Perhaps I could ask something else regarding the operating leverage angle. I believe you clearly observed a decline in adjusted operating expenses from one quarter to the next during this period, with truly strong leverage, and maybe you don't anticipate that continuing as a lasting pattern across roughly the next 5 quarters, but some additional commentary about your capacity to generate further operating leverage within the business would be useful.
Yes, sure. We will continually — please, Ed, go ahead. Yes, why don't you handle that? Please proceed.
Right. So operating expenses — like we mentioned earlier — the business model we have today already has a lot of leverage built into it. So, as I noted, when you look at it on a cash basis, it was in fact slightly higher, roughly $2 million compared with a year ago. And the main reason behind that comes down to our bonuses and variable compensation following the outperformance we're seeing on the top line this year. So if you take that out of the picture, you can basically expect the operating expense run rate on a cash basis to stay fairly steady.
Thanks, operator, and thanks to everyone for being with us today. It's a pleasure to keep building on the strong momentum we have operationally and financially. Our foundation is solid, the strategy centered on patients is delivering, and we feel confident about what lies ahead. Everything shared today strengthens our conviction in our capacity to reach both the goals we've set for the near term and our objectives for growth over the long term. I stay deeply optimistic regarding the future of our business and the opportunities in front of us; we look forward to talking with all of you once more on the next earnings call and to meeting many of you at the investor conferences and one-on-one meetings taking place over the coming weeks. Wishing each of you a wonderful rest of your day and a wonderful holiday season with your families and friends.
Thanks, Mr. Silvestro. As we wrap up today's call, I want to read the company's safe harbor statement, which contains key cautions about forward-looking statements we've made during this call. Anything management has said today could include forward-looking statements as defined under Section 27A and the Securities Act of 1993, as amended, along with Section 21E of the Securities Act of 1934 as amended; these forward-looking statements would not be used — should not be used to make investment decisions. Terms like anticipate, estimate, expect, possible and seeking, plus similar expressions, are how forward-looking statements get identified. They may speak only to the date that such statements are made. Today's call contains forward-looking statements. These cover how we see pharma companies, patients, and prescribers connecting; what our value is; our plans for growth; how we create shareholder value; becoming a Rule of 40 company; our estimated 2025 revenue and adjusted EBITDA ranges; capturing greater market share; expanding our participation in the pharma industry's digital ecosystem; our technology and growth opportunities; and building a strong operational and financial momentum. Management's expectations for the rest of the year are also forward-looking statements. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise. Risks and uncertainties are inherent to forward-looking statements, and some of them can't be predicted or qualified. What we actually achieve down the road, along with developments still to come, might wind up looking quite different from anything these forward-looking statements describe, envision, or suggest. Among the risks and uncertainties such statements carry are several, though this list isn't exhaustive: how government regulation affects us, matters of compensation, relying heavily on a small, concentrated set of customers, cybersecurity events capable of throwing operations into disarray, staying abreast of technology as it expands and changes, preserving our connections to electronic prescription platforms as well as electronic health records networks, plus additional significant risks covered in the company's annual report on Form 10-K covering the year that closed December 31, 2024, and in other documents the company has submitted or might submit later on with the SEC. Once those documents get submitted, you'll be able to find them both on the company's site and through the SEC's site, sec.gov. As we wrap up this call, just a note that a replay of the audio from today will be posted later tonight and will stay up for twelve months under the Investors area of the company's website. We appreciate your participation today. That brings this call to a close, so feel free to hang up whenever you're ready.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete OptimizeRx Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to OptimizeRx Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.